U.S. Legislation Passed to Promote Research and Awareness of Scleroderma PDF Print E-mail
Saturday, 02 October 2010 00:50
The Scleroderma Foundation (U.S.) has applauded the U.S. House of Representatives for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI). This bipartisan legislation gives hope to the estimated 300,000 Americans and their families living with this devastating disease.

The "Scleroderma Research and Awareness Act" will:
Direct the National Institutes of Health to intensify and coordinate activities relating to scleroderma, including:
  • Research on etiology and the development of new treatments.
  • Evaluate new treatments through clinical trials.
  • Research on the relationship between scleroderma and secondary conditions including: pulmonary hypertension, gastroparesis, Raynaud's phenomenon and Sjorgen's syndrome
  • Support for the training of new investigators
Direct the Centers for Disease Control and Prevention to establish a scleroderma public awareness campaign highlighting disease symptoms, prevalence, related conditions, and the importance of early diagnosis.

"The Scleroderma Foundation is proud to be in the forefront of advocating for greater research for this devastating disease," commented Joseph P. Camerino, Ph.D., Chair of the Foundation's National Board of Directors. "With the passage of this landmark legislation, the scleroderma community has even greater hope that a cure will be found."

For further information, please visit the source article here.
 
More articles :

» Rituximab for Scleroderma: Does Something Finally Work?

Kevin Deane, MDPosted: 03/10/2010Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle StudyDaoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280BackgroundMultiple drugs have been tried in...

» Biomarkers Predict Lung Decline in Systemic Sclerosis

Predicting risk of pulmonary fibrosis and pulmonary hypertension is an urgent priority in systemic sclerosis. Lung function often declines rapidly in the first years after diagnosis, and interstitial lung disease (ILD), although highly variable in...

» Survival In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc) and one of the leading causes of morbidity and mortality in this disease. Although several recent studies have suggested an improvement in the prognosis of...

» Vascular Changes in Bleomycin-Induced Scleroderma

Toshiyuki Yamamoto and Ichiro KatayamaDepartment of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, JapanDepartment of Dermatology, Osaka University, Yamadaoka 2-2, Suita, Osaka 565-0871, JapanReceived 6 June 2011;...

» Multidisciplinary Therapy May Improve Systemic Sclerosis

For patients with (SSc), a multidisciplinary program offers better improvement of grip strength, maximal mouth opening (MMO), six-minute walk distance (6MWD), and SSc Health Assessment Questionnaire (HAQ) score than regular outpatient care,...

» Finding Reliable Health Information Online

As Internet users quickly discover, an enormous amount of health information is available online. Finding accurate and reliable information on genetic and rare diseases among the millions of online sources is a difficult task for almost everyone. We...